1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > North American Intrauterine Contraceptive Devices Market by Type - Forecast to 2019

The North America intrauterine contraceptive devices market is estimated to grow at a CAGR of 0.3% from 2014 to 2019. The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of the Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing expenses related to abortion, funds/grants for IUCD products, and technological advancements. However, high costs of treatment, threat of pelvic inflammatory infection (PID), threat of ectopic pregnancy, high rate of complications during unplanned pregnancy, and the need for compulsory assistance of medical professionals hamper the growth of the IUCD market. Moreover, the rising number of players in this segment and technological advancements create growth opportunities for the North America intrauterine contraceptive devices market in these regions.

In this report, the North America intrauterine contraceptive devices market has been broadly classified on the basis of types, which includes Hormonal IUCD and Copper IUCD. The hormonal IUCD market segment accounted for the largest market share of 83.4% of the North American intrauterine contraceptive devices market. Factors such as safety, easy removal, lighter periods, and the increasing adoption of hormonal IUD products such as Mirean and Skyla in the U.S. drive the growth of this market.

Geographically, the U.S. is estimated to command the largest share of 93.0% of the North America intrauterine contraceptive devices market in 2014, followed by Canada. The intrauterine contraceptive devices market in the U.S. is primarily driven by the Affordable Care Act and technological advancements. However, stringent regulatory and reimbursement policies in the U.S. and the threat of PID infection hamper the growth of the intrauterine contraceptive devices market in this region.

The North America intrauterine contraceptive devices market is a competitive market with a number of market players. As of 2014, the North America intrauterine contraceptive devices market is estimated to be dominated by Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and Medicines360 (Ireland). New product launches & partnerships, agreements, collaborations, and joint ventures are the major strategies adopted by most market players to achieve growth in the North America intrauterine contraceptive devices market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis—market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging- and high-growth segments of the North America intrauterine contraceptive devices market, high-growth regions & countries & their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both the established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms that purchase the report could use any one or a combination of five strategies that include market penetration, product development/innovation, market development, market diversification, and competitive assessment to strengthen their market share.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on intrauterine contraceptive devices offered by top players in the North America intrauterine contraceptive devices market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the North America intrauterine contracep

Table Of Contents

North American Intrauterine Contraceptive Devices Market by Type - Forecast to 2019
TABLE OF CONTENTS

1 INTRODUCTION 8
1.1 OBJECTIVES OF THE STUDY 9
1.2 MARKET SEGMENTATION and COVERAGE 10
2 RESEARCH METHODOLOGY 11
2.1 INTEGRATED ECOSYSTEM OF INTRAUTERINE CONTRACEPTIVE DEVICES MARKET 11
2.2 ARRIVING AT THE INTRAUTERINE CONTRACEPTIVE DEVICES MARKET SIZE 12
2.2.1 TOP-DOWN APPROACH 12
2.2.2 BOTTOM-UP APPROACH 12
2.2.3 MACRO INDICATOR-BASED APPROACH 14
2.3 ASSUMPTIONS 14
3 EXECUTIVE SUMMARY 16
4 MARKET OVERVIEW 18
4.1 INTRODUCTION 18
4.2 MARKET DRIVERS and INHIBITORS 19
4.3 KEY MARKET DYNAMICS 23
5 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 26
5.1 INTRODUCTION 27
5.2 COPPER IUD 27
5.3 HORMONAL IUD 28
5.4 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET 29
5.5 NORTH AMERICA hormonal iud MARKET, BY country 30
5.6 NORTH AMERICA COPPER IUD MARKET, BY COUNTRY 31
6 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY PRODUCT 32
6.1 MIRENA 32
6.1.1 PRODUCT POSITIONING AND PROMOTIONS OF MIRENA 33
6.2 SKYLA 34
6.2.1 PRODUCT POSITIONING AND PROMOTIONS OF SKYLA 35
6.3 PARAGARD 36
6.3.1 PRODUCT POSITIONING AND PROMOTIONS OF PARAGARD 37
6.4 ESSURE 38
6.4.1 PRODUCT POSITIONING AND PROMOTIONS OF ESSURE 38

6.5 PIPELINE PRODUCTS 39
6.5.1 LEVOSERT 40
7 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET,
BY GEOGRAPHY 42
7.1 INTRODUCTION 43
7.2 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET 44
7.2.1 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES (IUCD) MARKET, BY TYPE 45
7.2.2 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 47
7.3 CANADA intra-uterine contraceptice devices MARKET 49
7.3.1 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE 50
8 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPETITIVE LANDSCAPE 51
8.1 U.S. INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS 51
8.2 CANADA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS 52
8.3 MERGERS and ACQUISITIONS 53
8.4 REGULATORY APPROVALS 53
8.5 PARTNERSHIP 54
8.6 COLLABORATION 54
9 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY COMPANY 55
9.1 BAYER HEALTHCARE AG (SUBSIDIARY OF BAYER AG) 55
9.1.1 OVERVIEW 55
9.1.2 KEY FINANCIALS 56
9.1.3 PRODUCT PORTFOLIO 56
9.1.4 RELATED DEVELOPMENTS 57
9.1.5 SWOT ANALYSIS 58
9.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 59
9.2.1.1 OVERVIEW 59
9.2.2 PRODUCT PORTFOLIO 60
9.2.3 SWOT ANALYSIS 61
9.3 ACTAVIS PLC 62
9.3.1 OVERVIEW 62
9.3.2 PRODUCT AND SERVICE OFFERINGS 63
9.3.3 RELATED DEVELOPMENTS 63
9.4 MEDICINES360 64
9.4.1 OVERVIEW 64
9.4.2 FINANCIALS 64
9.4.3 PRODUCT AND SERVICE OFFERINGS 64
9.4.4 RELATED DEVELOPMENTS 64
9.5 TRIMEDIC SUPPLY NETWORK LTD. 65
9.5.1 OVERVIEW 65
9.5.2 FINANCIALS 65
9.5.3 PRODUCTS AND SERVICE OFFERINGS 65
9.6 MEDISAFE DISTRIBUTION INC. 66
9.6.1 OVERVIEW 66
9.6.2 FINANCIALS 66
9.6.3 PRODUCT AND SERVICES OFFERINGS 66
9.6.4 RELATED DEVELOPMENTS 66
9.7 PACE PHARMACEUTICALS, INC. 67
9.7.1 OVERVIEW 67
9.7.2 FINANCIALS 67
9.7.3 PRODUCTS 67
9.7.4 RELATED DEVELOPMENTS 67
10 APPENDIX 68
10.1 RELATED REPORTS 68
10.2 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 68
10.2.1 RT SNAPSHOTS 69



LIST OF TABLES


TABLE 1 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: MACRO INDICATORS, BY COUNTRY, 2013 (ABORTION PER 1000 WOMEN AGES 15-44) 14
TABLE 2 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: DRIVERS AND INHIBITORS 19
TABLE 3 GLOBAL INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET: COMPARISION WITH GLOBAL FEMALE CONTRACEPTIVES MARKET, 2013-2019 (USD MN) 23
TABLE 4 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY COUNTRY, 2013-2019 (USD MN) 24
TABLE 5 NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE DEVICES MARKET, BY TYP,
2013-2019 (USD MN) 25
TABL

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.